Limits...
Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial.

Sinha A, Gupta SS, Chellani H, Maliye C, Kumari V, Arya S, Garg BS, Gaur SD, Gaind R, Deotale V, Taywade M, Prasad MS, Thavraj V, Mukherjee A, Roy M - BMJ Open (2015)

Bottom Line: By intention-to-treat analysis, the risk of PSBI among infants in the overall population of LBW infants was not statistically significant (RR 0.79 (95% CI 0.56 to 1.03)).Probiotics reduced median days of hospitalisation (6 days vs 3 days in probiotics) (p=0.018) but not the risk of hospitalisation (RR 0.66 (95% CI 0.42 to 1.04).Daily supplementation of LBW infants with probiotics VSL#3 (10 billion cfu) for 30 days led to a non-significant 21% reduction in risk of neonatal sepsis.

View Article: PubMed Central - PubMed

Affiliation: Department of Reproductive and Child Health, Indian Council of Medical Research, New Delhi, Delhi, India.

No MeSH data available.


Related in: MedlinePlus

Participant flow through the trial.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499724&req=5

BMJOPEN2014006564F1: Participant flow through the trial.

Mentions: Between January 2009 and November 2011, 5927 LBW newborn infants were screened and 1340 eligible LBW infants were enrolled (figure 1). Of the 5927 screened, 4587 were excluded (reasons given in figure 1). The probiotic and placebo groups were comparable with regard to baseline characteristics such as mode of delivery, mean birth weight, mother's schooling, religion of the family, standard of living index (SLI), and maternal morbidities during current pregnancy (table 1).


Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial.

Sinha A, Gupta SS, Chellani H, Maliye C, Kumari V, Arya S, Garg BS, Gaur SD, Gaind R, Deotale V, Taywade M, Prasad MS, Thavraj V, Mukherjee A, Roy M - BMJ Open (2015)

Participant flow through the trial.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499724&req=5

BMJOPEN2014006564F1: Participant flow through the trial.
Mentions: Between January 2009 and November 2011, 5927 LBW newborn infants were screened and 1340 eligible LBW infants were enrolled (figure 1). Of the 5927 screened, 4587 were excluded (reasons given in figure 1). The probiotic and placebo groups were comparable with regard to baseline characteristics such as mode of delivery, mean birth weight, mother's schooling, religion of the family, standard of living index (SLI), and maternal morbidities during current pregnancy (table 1).

Bottom Line: By intention-to-treat analysis, the risk of PSBI among infants in the overall population of LBW infants was not statistically significant (RR 0.79 (95% CI 0.56 to 1.03)).Probiotics reduced median days of hospitalisation (6 days vs 3 days in probiotics) (p=0.018) but not the risk of hospitalisation (RR 0.66 (95% CI 0.42 to 1.04).Daily supplementation of LBW infants with probiotics VSL#3 (10 billion cfu) for 30 days led to a non-significant 21% reduction in risk of neonatal sepsis.

View Article: PubMed Central - PubMed

Affiliation: Department of Reproductive and Child Health, Indian Council of Medical Research, New Delhi, Delhi, India.

No MeSH data available.


Related in: MedlinePlus